Antidepressant drug therapy for bulimia: current status.
More than 30 reports, including 9 placebo-controlled, double-blind studies, have assessed the efficacy of various medications, mostly antidepressants, for the treatment of bulimia. A critical review of the available data suggests that antidepressants, and possibly other thymoleptic agents, are clearly superior to placebo for the treatment of bulimia; the studies have not identified specific subgroups of bulimic patients who are, or are not, candidates for these agents; and tentatively, these agents may benefit major affective disorder and bulimia via similar mechanisms.
D000928:Antidepressive Agents / Q000627:therapeutic use*; D016642:Bupropion; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy; D004311:Double-Blind Method; D001068:Feeding and Eating Disorders / Q000188:drug therapy*; D005277:Fenfluramine / Q000627:therapeutic use; D006801:Humans; D006963:Hyperphagia / Q000150:complications / Q000188:drug therapy*; D008094:Lithium / Q000627:therapeutic use; D016651:Lithium Carbonate; D008694:Methamphetamine / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009627:Nomifensine / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D010919:Placebos; D011427:Propiophenones / Q000627:therapeutic use; D014635:Valproic Acid / Q000627:therapeutic use
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D010919:Placebos; D011427:Propiophenones; D016642:Bupropion; D009627:Nomifensine; D016651:Lithium Carbonate; D005277:Fenfluramine; D008694:Methamphetamine; D014635:Valproic Acid; D010672:Phenytoin; D008094:Lithium